Notice of Intent to Sole Source – Oncotype DX Cancer Testing Services

The Defense Health Agency (DHA) is issuing a sole‑source, firm‑fixed‑price contract to Genomic Health, Inc. for the Oncotype DX cancer‑testing service to support eligible patients at Mike O’Callaghan Military Medical Center, Nellis AFB, Nevada. The contractor will supply specimen‑submission kits, perform the proprietary genomic tumor test at its own laboratory, deliver a written report with interpretation, and return the original tissue blocks or unstained slides to the medical center. Interested vendors must submit a capability statement by 10:00 a.m. PDT on 11 September 2026; no competitive quotations are being solicited. The base period is one year (16 Sep 2026‑15 Sep 2027) with up to four 12‑month options and a possible six‑month extension. • Sole‑source award to Genomic Health, Inc. (Exact Sciences) • Service: Oncotype DX branded genomic tumor testing and reporting • Location: Mike O’Callaghan Military Medical Center, Nellis AFB, Nevada • Period of performance: 12‑month base, up to five additional periods (options) • Submission: Capability statement ≤ 6 pages, due 11 Sep 2026, 10:00 a.m. PDT • No phone inquiries; contact via email (Dominic Gonzales)